Home

Andrew R Allen

CIK 1374539 · PRESIDENT AND CEO · last filed 2026-06-18

Andrew R Allen is a PRESIDENT AND CEO who has filed 48 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for CGEM, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$11.9M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

8

Total Filings

48

Lifetime Open-Market Net

-$11.93M

Filer Profile

Reported Address
2525 28TH STREET
SUITE 200
BOULDER, CO 80301
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CGEM Director — $21.00 — $0 2 2026-06-18
Adaptimmune Therapeutics PLC (ADAP) Delisted Director — $0.06 — $0 3 2024-07-01
Gritstone bio, Inc. (GRTS) Delisted PRESIDENT AND CEO 1,310,360 $0.03 $42.2K -$18.2K 9 2024-06-26
TCR2 THERAPEUTICS INC. (TCRR) Delisted Director — $1.48 — $0 6 2023-06-01
Sierra Oncology, Inc. (SRRA) Delisted Director 0 $54.99 $0 $108.2K 7 2022-07-01
Epizyme, Inc. (EPZM) Delisted Director 20,560 $1.47 $30.2K $0 8 2021-06-15
Clovis Oncology, Inc. (CLVS) Delisted See Remarks 192,519 $0.08 $15.6K -$12.02M 8 2015-03-04
PHARMION CORP (PHRM) Delisted Chief Medical Officer, EVP 40,200 — — $0 4 2007-12-07

Recent Filings

48 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 CGEM Grant (A) — $0 EDGAR
2025-08-08 CGEM Grant (A) — $0 EDGAR
2024-07-01 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2024-06-26 Gritstone bio, Inc. (GRTS) Delisted Gift (G) −650,000 $0 EDGAR
2024-05-17 Gritstone bio, Inc. (GRTS) Delisted Mixed +23,610 -$18.2K EDGAR
2024-02-05 Gritstone bio, Inc. (GRTS) Delisted Grant (A) +105,000 $0 EDGAR
2023-07-05 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2023-07-03 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2023-06-01 TCR2 THERAPEUTICS INC. (TCRR) Delisted Disp (D) — $0 EDGAR
2023-02-06 Gritstone bio, Inc. (GRTS) Delisted Grant (A) +738,550 $0 EDGAR
Showing 1–10 of 48
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.